ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Protein Sciences Corp. has been awarded a $35 million contract by the Department of Health & Human Services to pursue a new method for making influenza vaccines. PSC inserts flu virus genes into insect virus cells that can be replicated rapidly for use in a vaccine. If extended up to five years, the development contract could be worth $147 million for the Connecticut-based vaccine developer. Meanwhile, PSC creditors filed a lawsuit earlier this month asking that the company be put into bankruptcy and its management replaced. Among the creditors, Emergent BioSolutions wants to claim nearly all of PSC's assets as collateral for a $10 million loan it made to keep PSC operating until Emergent either acquired PSC assets or was repaid.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X